Imperial Innovations
VC Fund
London, United Kingdom
Imperial Innovations is a technology commercialization and venture capital investor that focuses on technology. Imperial Innovations no longer invests in startups and now functions as the technology-transfer office of Imperial College.Imperial Innovations is focused on commercialising leading UK academic research sourced from the 'goldentriangle' formed between Cambridge, Oxford and London. We are a technology commercialisation company that combines the activities of technology transfer, intellectual property protection and licensing, company incubation and investment. Innovations is focused on commercialising the most promising UK academic research across a broad range of technology sectors, and has developed particular expertise in: therapeutics, medtech, engineering and materials and information communication technology.
- Total investments:
- 98
- Last investment:
- Lead investor:
- 49%
- Fund size:
- $178M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Imperial Innovations invests in
Stages Imperial Innovations invests in
Countries Imperial Innovations invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Parker
|
|||
Graham Hewson
|
|||
Jon Edington
|
|||
Laura Guida
|
|||
William Rayner
|
Investment Focus
Industry
- Biotechnology 24 (24%)
- Health Care 18 (18%)
- Medical 11 (11%)
- Therapeutics 9 (9%)
- Medical Device 9 (9%)
Stage
- Series A 25 (26%)
- Funding Round 24 (24%)
- Seed 12 (12%)
- Series C 8 (8%)
- Series B 7 (7%)
Country
- United Kingdom 53 (54%)
- United States 5 (5%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
David Parker
Venture Partner
|
Venture Partner | Total investments: 1 | Find email | |
|
Graham Hewson
Incubator Manager
|
Incubator Manager | Total investments: 0 | Find email | |
|
Jon Edington
Partner
|
Partner | Total investments: 11 | Find email | |
|
Laura Guida
Head Of Patent And Licence Management
|
Head Of Patent And Licence Management | Total investments: 0 | Find email | |
|
William Rayner
Company Secretary, General Counsel
|
Company Secretary, General Counsel | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Enterprise Therapeutics
|
Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life. | $5.2M / Nov 10, 2016 | |
Resolver
|
Resolver is a unique, independent online resolution service. We offer one place and one process to connect consumers directly to the people who can resolve their customer service issues. Our system is focused on communication and fair, efficient resolution. We help consumers get their voices heard effectively, so businesses get their issuesresolved more efficiently. This way, the consumer is happy with the outcome and the business retains the customer.The Resolver platform offers fully online, end-to-end arbitration and dispute resolution, providing a fast and cost-efficient way to resolve disputes between two third parties.For businesses, Resolver offers value-added services, providing an enhanced issue-resolution process and real-time consumer feedback insight at every touchpoint using advanced AI programming systems. | $3.7M / Series A / Oct 21, 2016 | |
Concirrus
|
Concirrus is a leading Insurtech specialising in transforming the future of risk selection, pricing and claims using the latest developments in data analytics, AI, machine learning, and digitalisation. Concirrus' intelligence platform Quest, helps organisations improve loss ratios, reduce operational expense and access increased deal sizes,and new trading relationships. By capturing and understanding customer behaviour, delivering data-rich insights at scale, underwriting teams are empowered to make rapid data-driven decisions. Over 20 market-leading companies including Marsh, Beazley, Hiscox, Chaucer and Willis Re trust Concirrus’ technology to power their risk making decisions. Headquartered in London with international presence, Concirrus has a 100-strong team of experts that specialise in data analytics, AI and machine learning, as well as having a rich understanding of the global insurance market. | $3.9M / Series A / Sep 27, 2016 | |
ThisWay
|
ThisWay uses 'Signature AI' and blockchain technology provides individualized machine learning and data security. Its first enterprise solution is AI4Jobs. It provides 20X more efficient and accurate sourcing of qualified talent, while also increasing diversity and inclusion so that ROI is optimized. In just a couple of minutes you willreceive a matched and scored list of the candidates you are looking for. No integration is required but all are available. | $2.1M / Seed / Sep 27, 2016 | |
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $32.7M / Series A / Sep 21, 2016 | |
Oxular
|
Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs. | $20.6M / Series A / Jul 19, 2016 | |
Abingdon Health
|
Abingdon Health are building an innovative technology-led company focused on providing rapid and near-patient medical diagnostic testing solutions.Abingdon Health are developing, manufacturing and selling products and systems that support the migration of testing from the laboratory closer to the patient with the intention of improving bothclinical and economic healthcare outcomes. Our initial clinical focus is on developing a range of rapid testing products in the areas of hematology oncology, specifically B-cell dyscrasias.We will use our expertise in immunodiagnostics, plastic electronics, hardware and software, to develop the next generation of testing systems that meet the needs of our customers. Our current platform development is looking to provide customers with a multiplexed, portable, cost-effective and connected rapid testing solution. | $3.9M / Jul 13, 2016 | |
Econic Technologies
|
Econic Technologies was born from a vision where catalyst chemistry is used to turn waste CO2 into positive economic and environmental potential. Incorporating waste CO2 as a feedstock for polymer preparation using our novel catalysts reduces the reliance on expensive fossil fuels, turning scientific research into business advantage for plasticsmanufacturers while delivering environmental gain for the benefit of all.This vision was crystallized by Professor Charlotte Williams, then at Imperial College London, and now Professor of Inorganic Chemistry in the Department of Chemistry at the University of Oxford. It was initially supported by investment from Touchstone Innovations, now IP Group plc, and Norner Verdandi, and now includes backing by Woodford Investment Management, Jetstream Capital, and OGCI Climate Investments.Much progress has been made since then.Econic’s catalyst technologies have been patented, validated in pilot operations and continue to secure additional investment.A talented team of scientists, engineers, and commercial managers now conduct their cutting-edge work in a state-of-the-art facility at Alderley Park, the internationally renowned science hub south of Manchester.All of our efforts are intently focused on the future. A future where waste CO2, a damaging greenhouse gas, is turned into a commercial and environmental gain. A future that starts now. | $6.5M / Jul 06, 2016 | |
Storm Therapeutics
|
Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $15.7M / Series A / Jun 28, 2016 | |
Featurespace
|
Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB. | $9M / May 31, 2016 | |
| See all 98 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Imperial Innovations invest in?
Imperial Innovations invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Funding Round stage. Most of the 98 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Imperial Innovations?
Public channels for Imperial Innovations include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Imperial Innovations?
The team at Imperial Innovations includes David Parker (Venture Partner), Graham Hewson (Incubator Manager) and Jon Edington (Partner), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
